FoRx Therapeutics AG appoints Frank Zenke as Chief Scientific Officer

Basel, Switzerland, 01 August 2023 – FoRx Therapeutics, an incorporated privately held company developing first-in-class compounds for cancer treatment, today announces the appointment of Frank Zenke as Chief Scientific Officer.

With more than 20 years of pharma industry experience, Frank is a highly respected leader in oncology drug discovery and development with a particular focus on DNA Damage Response (DDR) pathways. In his most recent role, Global Head of DDR Research in the healthcare division of Merck KGaA, Darmstadt, and its US subsidiary EMD Serono, Billerica, Frank has played a pivotal role in discovering and developing small molecule inhibitors targeting the key DDR kinases ATR, ATM, and DNA-PK. Collaborating with academic centers, biotechnology, and pharma partners, Frank has driven the exploration of new target classes, and shaped innovative clinical development directions through fundamental translational research. Frank studied biology at the Ruhr University of Bochum and Heinrich Heine University of Düsseldorf where he received his diploma and PhD degrees. He carried out his postdoctoral training at The Scripps Research Institute in La Jolla, California.

About FoRx Therapeutics
FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways activated in cancer. Drawing on discoveries by Prof. Thanos Halazonetis and Dr. Sotirios Sotiriou, FoRx was co-founded in 2019 with M Ventures, Novartis Venture Fund and Omega Funds along with Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), and LSP (Life Science Partners, now EQT Life Sciences). For more information, visit www.forxtherapeutics.com